Introducción
Capítulo A.6
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Jaume Morey
Misceláneo
Capítulo J.6
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto-Tagle & Marina Romero
Misceláneo
Capítulo J.2
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Montserrat Pamias
El Programa de acción mundial para superar las brechas en salud mental (mhGAP)1 fue
lanzado por la Organización Mundial de la Salud (OMS) en el año 2008. En 2010, se
lanzó la Guía de Intervención mhGAP (GI‐mhGAP) (1) y se comenzó a aplicar en cinco
países (Etiopía, Jordania, Nigeria, P...anamá y Sierra Leona) dentro de un proyecto
piloto, bajo la supervisión de la OMS. Panamá lo puso en funcionamiento utilizando la
versión española del mhGAP; los otros cuatro países usaron la versión inglesa1.
more
[Updated 2015]
SCOPING QUESTION: What is the effectiveness of psychosocial interventions (including caregiver skills training) for behavioural disorders in children and adolescents?
A FACT SHEET FROM THE OFFICE ON WOMEN’S HEALTH
www.womenshealth.gov | 1-800-994-9662
A tool for measuring alcohol policy implementation
Q8: What is the effectiveness, safety and role of pharmacological interventions, by non-specialized health care providers, for the broad category of Disruptive Behaviour Disorders (DBDs), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid (but not exclusively) Attention-Deficit ...Hyperactivity Disorder (ADHD)?
more
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
(Updated 2015)
Scoping question: What is the effectiveness of caregiver skills training in the management of children and adolescents with developmental disorders?
Children's Health and the Environment WHO Training Package for the Health Sector World Health Organization
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q6: Can dementia be diagnosed at first or second level care by non-specialist health care providers? What should be the assessment process for the diagnosis of dementia?